REFERENCES
- C. Katlama and others. Efficacy of TMC-114/r in 3-class experi-enced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Abstract 164LB. CROI. February 22–25, 2005. Boston, MA.
- S. Ford and others. 640385, a novel HIV-1 protease inhibitor: safety and pharmacokinetics following repeat administra-tion with and without ritonavir in healthy subjects. Abstract 563. 12th CROI. February 22–25, 2005. Boston, MA.
- M. P. de Bethune and others. TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharma-cokinetic profile. Abstract 556. 12th CROI. February 22–25, 2005. Boston, MA.
- F. Goebel and others. TMC-278: potent anti-HIV activity in antiretroviral therapy-naive patients. Abstract 160. 12th CROI. February 22–25, 2005. Boston, MA.
- M Baba and others. TAK-652, a novel small molecule CCR5 antagonist with potent anti-HIV-1 activity. Abstract 541. 12th CROI. February 22–25, 2005. Boston, MA.
- C. Tremblay and others. TAK-652, a novel small molecule in-hibitor of CCR5 has favorable anti-HIV interactions with other antiretrovirals in vitro. Abstract 542. 12th CROI. Feb-ruary 22–25, 2005. Boston, MA.
- H. Nakata and others. Greater synergistic anti-HIV effects upon combinations of a CCR5 inhibitor AK602/0N04128/ GW873140 with CXCR4 inhibitors than with other anti-HIV drugs. Abstract 543. 12th CROI. February 22–25, 2005. Boston, MA.
- S. Sparks and others. Prolonged duration of CCR5 occupancy by 873140 in HIV-negative and HIV-positive subjects. Ab-stract 77. 12th CROI. February 22–25, 2005. Boston, MA.
- M. Westby and others. Structurally-related HIV co-receptor antagonists bind to similar regions of CCR5 but have differ-ential activities against UK-427,857-resistant primary iso-lates. Abstract 96. 12th CROI. February 22–25, 2005. Bos-ton, MA.
- D. Martin and others. The safety, tolerability, and pharmacoki-netics of multiple oral doses of PA-457, the first-in-class HIV maturation inhibitor, in healthy volunteers. Abstract 551. 12th CROI. February 22–25, 2005. Boston, MA.
- D. Martin and others. PA-457, the first-in-class maturation in-hibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients. Abstract 159. 12th CROI. Feb-ruary 22–25, 2005. Boston, MA.
- S. Little and others. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients. Ab-stract 161. 12th CROI. February 22–25, 2005. Boston, MA.